The financing will also support the further advancement of Alumis precision data analytics and multi-platform approach to explore ESK-001s potential application in other autoimmune indications, as well as A-005, a TYK2 inhibitor for the treatment of neuroinflammatory and neurodegenerative diseases, and its earlier-stage internal pipeline programs. "We are pleased to announce our successful Series C financing and we are grateful for the support of our strong investor syndicate, a group that shares our commitment to transforming the treatment paradigm for patients living with immune-mediated diseases, said Martin Babler, Alumis President and Chief Executive Officer. We are proud to invest in and work with this team again to support their continued growth and success as they explore both the full potential of their lead program, ESK-001, in immune-mediated diseases and the broad opportunity where the TYK2 pathway plays a key role. Alumis precision approach in this field focused on the application of data science and translational insights to validated targets that drive immune dysfunction will ultimately lead to better outcomes for patients, and we look forward to supporting the team as they work to realize that goal. Alumis lead candidate ESK-001 is a highly selective and potentially best-in-class allosteric tyrosine kinase 2 (TYK2) inhibitor that is currently being evaluated for the treatment of patients with moderate to severe plaque psoriasis, systemic lupus erythematosus (SLE), and non-infectious uveitis.